{"id":22066,"date":"2023-02-15T16:13:00","date_gmt":"2023-02-15T08:13:00","guid":{"rendered":"https:\/\/flcube.com\/?p=22066"},"modified":"2025-01-19T16:16:58","modified_gmt":"2025-01-19T08:16:58","slug":"brii-biosciences-publishes-positive-phase-ii-results-for-hbv-treatment","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=22066","title":{"rendered":"Brii Biosciences Publishes Positive Phase II Results for HBV Treatment"},"content":{"rendered":"\n

China’s Brii Biosciences (HKG: 2137<\/a>) has announced the publication of interim results from a Phase II study for its small interfering RNA (siRNA) drug candidate BRII-835 (VIR-2218) combined with BRII-179 (VBI-2601), an immuno-therapeutic drug candidate co-developed by VBI Vaccines, in chronic hepatitis B virus (HBV). The combination therapy induced a stronger anti-hepatitis B surface antigen (HBsAg) antibody response and improved HBsAg-specific T cell response compared to single drug treatments.<\/p>\n\n\n\n

Interim Results and Observations<\/strong>
At the 40th week of the study, it was observed that the level of HBsAg in two subjects in the combined treatment group decreased to at or below the lower limit of quantification. Additionally, a robust HBsAg-specific antibody response and T-cell response were observed. These results suggest that the combination therapy may offer significant benefits over monotherapy in the treatment of chronic HBV.<\/p>\n\n\n\n

BRII-835: Investigational siRNA for HBV<\/strong>
BRII-835, an investigational subcutaneous siRNA originated by Vir Biotechnology (NASDAQ: VIR<\/a>) to treat HBV, is the first of its kind in the clinics containing enhanced stable chemical potentiation (ESC+) technology. This technology is designed to improve stability and minimize off-target activity, which is expected to improve the treatment index. Brii Bio struck a licensing deal with Vir in 2020 to take exclusive development and commercialization rights to the drug in Greater China.<\/p>\n\n\n\n

BRII-179: Immuno-Therapeutic Drug Candidate<\/strong>
BRII-179 is formulated to target both B-cell and T-cell immunity through multiple mechanisms of action. These include neutralizing the circulating hepatitis B virus, blocking hepatitis B infection of hepatocytes mediated through Pre-S1, and enabling immune-mediated clearance of HBV-infected hepatocytes. The antigenic components of BRII-179 (VBI-2601) are the same as the three antigenic components of the preventive hepatitis B recombinant vaccine PreHevbrio, developed by VBI Vaccines, which has been approved for marketing in the United States.<\/p>\n\n\n\n

Functional Cure for HBV Infection<\/strong>
Brii Bio is also developing the combination therapy as a functional cure for HBV infection. Further data from the study is expected to be released later this year, providing more insights into the potential of this innovative treatment approach.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China’s Brii Biosciences (HKG: 2137) has announced the publication of interim results from a Phase…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[449,17,29,1219,1542,64,792,89],"class_list":["post-22066","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-brii-biosciences","tag-clinical-trial-results","tag-combination-therapy","tag-hkg-2137","tag-nasdaq-vir","tag-rnai-aso","tag-vir-biotechnology","tag-viral-hepatitis"],"yoast_head":"\nBrii Biosciences Publishes Positive Phase II Results for HBV Treatment - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China's Brii Biosciences (HKG: 2137) has announced the publication of interim results from a Phase II study for its small interfering RNA (siRNA) drug candidate BRII-835 (VIR-2218) combined with BRII-179 (VBI-2601), an immuno-therapeutic drug candidate co-developed by VBI Vaccines, in chronic hepatitis B virus (HBV). The combination therapy induced a stronger anti-hepatitis B surface antigen (HBsAg) antibody response and improved HBsAg-specific T cell response compared to single drug treatments.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=22066\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Brii Biosciences Publishes Positive Phase II Results for HBV Treatment\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=22066\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-15T08:13:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-19T08:16:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22066#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22066\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Brii Biosciences Publishes Positive Phase II Results for HBV Treatment\",\"datePublished\":\"2023-02-15T08:13:00+00:00\",\"dateModified\":\"2025-01-19T08:16:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22066\"},\"wordCount\":349,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Brii Biosciences\",\"Clinical trial results\",\"Combination therapy\",\"HKG: 2137\",\"NASDAQ: VIR\",\"RNAi \\\/ ASO\",\"Vir Biotechnology\",\"Viral hepatitis\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=22066#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22066\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=22066\",\"name\":\"Brii Biosciences Publishes Positive Phase II Results for HBV Treatment - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-02-15T08:13:00+00:00\",\"dateModified\":\"2025-01-19T08:16:58+00:00\",\"description\":\"China's Brii Biosciences (HKG: 2137) has announced the publication of interim results from a Phase II study for its small interfering RNA (siRNA) drug candidate BRII-835 (VIR-2218) combined with BRII-179 (VBI-2601), an immuno-therapeutic drug candidate co-developed by VBI Vaccines, in chronic hepatitis B virus (HBV). The combination therapy induced a stronger anti-hepatitis B surface antigen (HBsAg) antibody response and improved HBsAg-specific T cell response compared to single drug treatments.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22066#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=22066\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22066#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Brii Biosciences Publishes Positive Phase II Results for HBV Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Brii Biosciences Publishes Positive Phase II Results for HBV Treatment - Insight, China's Pharmaceutical Industry","description":"China's Brii Biosciences (HKG: 2137) has announced the publication of interim results from a Phase II study for its small interfering RNA (siRNA) drug candidate BRII-835 (VIR-2218) combined with BRII-179 (VBI-2601), an immuno-therapeutic drug candidate co-developed by VBI Vaccines, in chronic hepatitis B virus (HBV). The combination therapy induced a stronger anti-hepatitis B surface antigen (HBsAg) antibody response and improved HBsAg-specific T cell response compared to single drug treatments.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=22066","og_locale":"en_US","og_type":"article","og_title":"Brii Biosciences Publishes Positive Phase II Results for HBV Treatment","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=22066","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-02-15T08:13:00+00:00","article_modified_time":"2025-01-19T08:16:58+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=22066#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=22066"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Brii Biosciences Publishes Positive Phase II Results for HBV Treatment","datePublished":"2023-02-15T08:13:00+00:00","dateModified":"2025-01-19T08:16:58+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=22066"},"wordCount":349,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Brii Biosciences","Clinical trial results","Combination therapy","HKG: 2137","NASDAQ: VIR","RNAi \/ ASO","Vir Biotechnology","Viral hepatitis"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=22066#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=22066","url":"https:\/\/flcube.com\/?p=22066","name":"Brii Biosciences Publishes Positive Phase II Results for HBV Treatment - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-02-15T08:13:00+00:00","dateModified":"2025-01-19T08:16:58+00:00","description":"China's Brii Biosciences (HKG: 2137) has announced the publication of interim results from a Phase II study for its small interfering RNA (siRNA) drug candidate BRII-835 (VIR-2218) combined with BRII-179 (VBI-2601), an immuno-therapeutic drug candidate co-developed by VBI Vaccines, in chronic hepatitis B virus (HBV). The combination therapy induced a stronger anti-hepatitis B surface antigen (HBsAg) antibody response and improved HBsAg-specific T cell response compared to single drug treatments.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=22066#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=22066"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=22066#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Brii Biosciences Publishes Positive Phase II Results for HBV Treatment"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22066","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=22066"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22066\/revisions"}],"predecessor-version":[{"id":22067,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22066\/revisions\/22067"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=22066"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=22066"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=22066"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}